Barclays PLC Buys 30,095 Shares of Akoya Biosciences, Inc. (NASDAQ:AKYA)

Barclays PLC increased its stake in shares of Akoya Biosciences, Inc. (NASDAQ:AKYA) by 320.9% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 39,472 shares of the company’s stock after acquiring an additional 30,095 shares during the period. Barclays PLC owned about 0.08% of Akoya Biosciences worth $107,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also bought and sold shares of the company. Regal Investment Advisors LLC raised its holdings in Akoya Biosciences by 64.3% during the second quarter. Regal Investment Advisors LLC now owns 18,760 shares of the company’s stock worth $44,000 after acquiring an additional 7,340 shares in the last quarter. Bank of New York Mellon Corp raised its stake in Akoya Biosciences by 16.2% in the second quarter. Bank of New York Mellon Corp now owns 67,468 shares of the company’s stock valued at $158,000 after buying an additional 9,429 shares during the period. GSA Capital Partners LLP raised its stake in Akoya Biosciences by 87.4% in the third quarter. GSA Capital Partners LLP now owns 310,669 shares of the company’s stock valued at $845,000 after buying an additional 144,903 shares during the period. Finally, State Street Corp raised its stake in Akoya Biosciences by 4.2% in the third quarter. State Street Corp now owns 453,296 shares of the company’s stock valued at $1,233,000 after buying an additional 18,361 shares during the period. Institutional investors own 79.42% of the company’s stock.

Akoya Biosciences Price Performance

Akoya Biosciences stock opened at $2.66 on Thursday. Akoya Biosciences, Inc. has a 12 month low of $1.88 and a 12 month high of $6.31. The stock’s 50 day moving average is $2.48 and its 200-day moving average is $2.53. The company has a current ratio of 2.75, a quick ratio of 1.85 and a debt-to-equity ratio of 5.62. The company has a market capitalization of $131.84 million, a price-to-earnings ratio of -2.25 and a beta of 1.18.

Wall Street Analyst Weigh In

Several research firms have issued reports on AKYA. Craig Hallum lowered Akoya Biosciences from a “buy” rating to a “hold” rating and dropped their price objective for the company from $7.00 to $5.00 in a research note on Friday, November 15th. Canaccord Genuity Group dropped their price objective on Akoya Biosciences from $6.00 to $3.50 and set a “buy” rating on the stock in a research note on Friday, November 15th. Finally, Piper Sandler restated an “overweight” rating and issued a $3.00 price objective (down previously from $4.00) on shares of Akoya Biosciences in a research note on Tuesday, November 19th. Four investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat, Akoya Biosciences has an average rating of “Hold” and an average price target of $5.43.

Akoya Biosciences Profile

Akoya Biosciences, Inc, a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow.